ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences

LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present abstracts with pre-clinical data for its cystic fibrosis program at the 29 th Annual North American Cystic Fibrosis Conference (NACFC) in Phoenix, Arizona, October 8 – 10, 2015 and the 11 th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Leiden, The Netherlands, October 11 – 14, 2015. NACFC 'QR-010 Treatment for Cystic Fibrosis; Assessing the Airway-Mucus Barrier in Delivery', poster #214, will be presented October 8 th , 11:50 – 1:50pm MT and October 9 th , 7:30 – 8:45am MT. The poster will also be highlighted in the poster workshop session, 'New Therapies & Outcomes,' on October 10 th , 10:30 – 12:15pm MT. The abstract is available in a special issue of Pediatric Pulmonology . Investor and analyst event at NACFC On October 8 th at 6:30pm MT, ProQR management invites investors and analysts to an event with Brian Button, PhD, Assistant Professor of Medicine at University of North Carolina at Chapel Hill to further discuss the presented pre-clinical data. For more information or to RSVP, please contact Sariette Witte at [email protected] . OTS The abstract titled: 'QR-010 penetrates the mucus barrier in vitro and in vivo' will be presented in a poster during the conference. The abstract will be available on the OTS website prior to the conference. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012. ProQR Therapeutics N.V.: Smital Shah Chief Financial Officer T: +1 415 231 6431 [email protected] Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +49 89 2424 3494 [email protected]

The release as fetched from its publisher. proqr.com ↗